natgillin/translations-raw huggingface dataset:
However, there was no difference in the half-life and accumulation of irbesartan. 
Međutim, nije bilo razlika što se tiče poluvijeka i akumulacije irbesartana.
At 24 hours the reduction of blood pressure was 60-70 % of the corresponding peak diastolic and systolic responses at the recommended doses. 
U 24 sata snižavanje krvnog tlaka bilo je 60-70% vršnog dijastoličkog i sistoličkog odgovora pri preporučenim dozama.
The frequency of adverse reactions listed below is defined using the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to 
Učestalost nuspojava u nastavku teksta definira se na sljedeći način: vrlo često (≥ 1/10); često (≥ 1/100 do < 1/10); manje često (≥ 1/1.000 do < 1/100); rijetko (≥ 1/10.000 do < 1/1.000); vrlo rijetko (<
Irbesartan AUC and Cmax values were also somewhat greater in elderly subjects (≥ 65 years) than those of young subjects (18-40 years). 
Vrijednosti AUC i Cmax irbesartana također su bile nešto veće u starijih ispitanika (≥ 65 godina) u usporedbi s mlađima (18-40 godina).
Your doctor will normally advise you to stop taking Irbesartan Teva before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Irbesartan Teva. 
Vaš će Vam liječnik obično preporučiti da prestanete uzimati Irbesartan Teva prije nego što zatrudnite ili čim saznate da ste trudni te će Vam savjetovati da uzmete neki drugi lijek umjesto Irbesartana Teva.
Irbesartan has been studied in paediatric populations aged 6 to 16 years old but the current data are insufficient to support an extension of the use in children until further data become available (see sections 4.8, 5.1 and 5.2). 
Irbesartan je ispitivan na pedijatrijskoj populaciji u dobi od 6 do 16 godina, ali trenutni podaci nisu dostatni da bi podržali proširenje primjene na djecu, sve dok ne budu dostupni i daljnji podaci (vidjeti dijelove 4.8., 5.1. i 5.2.).
Irbesartan is a potent, orally active, selective angiotensin-II receptor (type AT1) antagonist. 
Irbesartan je snažan, oralno djelotvoran, selektivni antagonist receptora angiotenzina II (tip AT1).
Therefore, the use of irbesartan is not recommended. 
Stoga se ne preporučuje primjena irbesartana.
No specific information is available on the treatment of overdose with irbesartan. 
Nema dostupnih specifičnih podataka o liječenju predoziranja irbesartanom.
The dose may later be increased to 300 mg once daily depending on blood pressure response. 
Doza se kasnije može povećati na 300 mg jednom na dan, ovisno o vrijednostima krvnog tlaka.
After oral administration, irbesartan is well absorbed: studies of absolute bioavailability gave values of approximately 60-80 %. 
Nakon peroralne primjene irbesartan se dobro apsorbirao: ispitivanja apsolutne bioraspoloživosti pokazala su vrijednosti oko 60-80%.
When the individual components of the primary endpoint were analysed, no effect in all cause mortality was observed, while a positive trend in the reduction in ESRD and a significant reduction in doubling of serum creatinine were observed. 
Kad su se analizirale individualne komponente primarnog ishoda, nisu zabilježeni učinci na sve uzroke smrtnosti, dok je zabilježen pozitivan trend u smanjenju terminalne faze bubrežne bolesti i značajno smanjenje u udvostručavanju serumskog kreatinina.
Polydextrose (E1200) Titanium dioxide (E171) Hypromellose (E464) Macrogol 4000 
Film-ovojnica: polidekstroza (E1200) titanijev dioksid (E171) hipromeloza (E464) makrogol 4000
Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. 
Epidemiološki podaci koji se odnose na rizik od teratogenog učinka nakon uporabe ACE inhibitora tijekom prvog tromjesečja nisu bili dostatni za donošenje zaključaka; manji porast rizika, međutim, ne može se isključiti.
The most likely manifestations of overdose are expected to be hypotension and tachycardia; bradycardia might also occur from overdose. 
Najčešće očekivane manifestacije predoziranja su hipotenzija i tahikardija; zbog predoziranja može se pojaviti i bradikardija.
What you need to know before you take Irbesartan Teva Do not take Irbesartan Teva if you are allergic to irbesartan or to any of the other ingredients of this medicine (listed in section 6). 
Što morate znati prije nego počnete uzimati Irbesartan Teva Nemojte uzimati Irbesartan Teva ako ste alergični na irbesartan ili neki drugi sastojak ovog lijeka (naveden u dijelu 6).
Although consideration should be given to initiating therapy with 75 mg in patients over 75 years of age, dose adjustment is not usually necessary for elderly people. 
Iako za bolesnike starije od 75 godina treba razmotriti započinjanje terapije dozom od 75 mg, dozu obično nije potrebno prilagoditi u starijih osoba.
Patients with primary aldosteronism generally will not respond to antihypertensive medicinal products acting through inhibition of the renin-angiotensin system. 
Bolesnici s primarnim hiperaldosteronizmom općenito ne reagiraju na antihipertenzivne lijekove koji djeluju putem inhibicije renin-angiotenzinskog sustava.
In the 26-week open-label period of this trial the most frequent laboratory abnormalities observed were creatinine increases (6.5 %) and elevated CK values in 2 % of child recipients. 
otvorenom razdoblju ove studije, u trajanju od 26 tjedana, najčešće opažene laboratorijske abnormalnosti bile su povećana koncentracija kreatinina (6,5%) i povišene vrijednosti CK u 2% djece.
Such conditions should be corrected before the administration of irbesartan. 
Takva stanja treba korigirati prije primjene irbesartana.
HU-4042 Debrecen 
Pallagi út 13 HU-4042 Debrecen
This medicinal product does not require any special storage conditions. 
Lijek ne zahtjeva posebne uvjete čuvanja.
The maximal blood pressure lowering effect should be reached 4-6 weeks after beginning treatment. 
Maksimalan učinak na sniženje krvnog tlaka trebao bi se postići za 4-6 tjedana od početka liječenja.
Following oral or intravenous administration of 14C irbesartan, 80-85 % of the circulating plasma radioactivity is attributable to unchanged irbesartan. 
Nakon oralne ili intravenske primjene 14C irbesartana, 80-85% cirkulirajuće radioaktivnosti u plazmi odnosi se na nepromijenjeni irbesartan.
In particular, the addition of a diuretic such as hydrochlorothiazide has been shown to have an additive effect with irbesartan (see section 4.5). 
Posebice, pokazalo se da dodavanje diuretika, poput hidroklorotiazida, ima aditivni učinak s irbesartanom (vidjeti dio 4.5).
No dosage adjustment is necessary in elderly people. 
Stoga, nije potrebna prilagodba doze u starijih osoba.
How to store Irbesartan Teva Contents of the pack and other information 
Moguće nuspojave Kako čuvati Irbesartan Teva Sadržaj pakiranja i druge informacije
• Hypersensitivity to the active substance or to any of the excipients listed insection 6.1. 
• Preosjetljivost na djelatnu tvar ili neku od pomoćnih tvari navedenih u dijelu 6.1.
Available pharmacodynamic/toxicological data in rats have shown excretion of irbesartan or its metabolites in milk (for details see section 5.3). 
Dostupni farmakodinamički/toksikološki podaci iz ispitivanja na štakorima pokazali su da se irbesartan ili njegovi metaboliti izlučuju u mlijeko (za detalje vidjeti dio 5.3).
Irbesartan significantly reduced the relative risk in the primary combined endpoint of doubling serum creatinine, end-stage renal disease (ESRD) or allcause mortality. 
Irbesartan značajno snižava relativni rizik u primarnoj kombiniranoj mjeri ishoda udvostručenog serumskog kreatinina, terminalne faze bubrežne bolesti ili svih uzroka mortaliteta.
Peak plasma concentrations are attained at 1.5-2 hours after oral administration. 
Vršne koncentracije u plazmi postižu se 1,5 do 2 sata nakon oralne primjene.
Detailed information on this medicinal product is available on the website of the European Medicines Agency: http://www.ema.europa.eu 
Teva dostupne su na internetskoj stranici Europske agencije za lijekove: http://www.ema.europa.eu/.
Whilst there is no controlled epidemiological data on the risk with Angiotensin II Receptor Inhibitors (AIIRAs), similar risks may exist for this class of drugs. 
Iako ne postoje kontrolirani epidemiološki podaci o riziku kod primjene antagonista receptora angiotenzina II, slični rizici mogli bi postojati za ovu skupinu lijekova.
Pack size of 28 film-coated tablets in non-perforated calendar blisters. 
Pakiranje sa 28 filmom obloženih tableta u neperforiranim kalendarskim blisterima.
There is no experience regarding the administration of irbesartan in patients with a recent kidney transplantation. 
Nema iskustava s primjenom irbesartana u bolesnika kojima je nedavno transplantiran bubreg.
In vitro studies indicate that irbesartan is primarily oxidised by the cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect. 
In vitro ispitivanja upućuju da se irbesartan primarno oksidira pomoću enzima CYP2C9 citokroma P450; izoenzim CYP3A4 ima neznatan učinak.
As with similar medicines, rare cases of allergic skin reactions (rash, urticaria), as well as localised swelling of the face, lips and/or tongue have been reported in patients taking irbesartan. 
Kao i kod ostalih sličnih lijekova, zabilježeni su rijetki slučajevi alergijskih kožnih reakcija (osip, urtikarija), kao i lokalizirano oticanje lica, usnica i/ili jezika kod bolesnika koji su uzimali irbesartan.
There is no clinically important effect on serum uric acid or urinary uric acid secretion. 
Nema klinički važnog učinka na mokraćnu kiselinu u serumu ili na urinarno izlučivanje mokraćne kiseline.
Irbesartan Teva is unlikely to affect your ability to drive or use machines. 
Irbesartan Teva ne bi trebao utjecati na Vašu sposobnost upravljanja vozilima i strojevima.
If a child swallows some tablets, contact your doctor immediately. 
Ako dijete proguta tablete, odmah se javite svom liječniku.
The total body and renal clearance are 157-176 and 3-3.5 ml/min, respectively. 
Ukupni tjelesni klirens iznosi 157-176, a bubrežni klirens 3-3,5 ml/min.
Teva Pharmaceuticals Ireland L-Irlanda 
Malta Teva Pharmaceuticals Ireland
While this is not documented with irbesartan, a similar effect should be anticipated with angiotensin-II receptor antagonists. 
Iako to još nije potvrđeno za irbesartan, sličan učinak može se očekivati s antagonistima receptora angiotenzina II.
arthralgia, myalgia (in some cases associated with increased plasma creatine kinase levels), muscle cramps 
artralgija, mijalgija (u nekim slučajevima povezana s povećanom koncentracijom kreatin kinaze u plazmi), grčevi mišića
Irbesartan Teva is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely. 
Irbesartan Teva ne preporučuje se majkama koje doje, a Vaš liječnik može izabrati drugu terapiju ako želite dojiti, osobito ako se radi o dojenju novorođenčeta ili nedonoščeta.
potassium supplements salt substitutes containing potassium potassium-sparing medicines (such as certain diuretics) medicines containing lithium 
nadomjeske kalija nadomjeske soli koji sadrže kalij lijekove koji čuvaju kalij (kao što su neki diuretici) lijekove koji sadrže litij
Fertility and reproductive performance were not affected in studies of male and female rats even at oral doses of irbesartan causing some parental toxicity (from 50 to 650 mg/kg/day), including mortality at the highest dose. 
Nije zabilježen utjecaj na plodnost i reproduktivnu učinkovitost u istraživanjima na mužjacima i ženkama štakora, čak ni pri oralnim dozama irbesartana koje su uzrokovale određenu parentalnu toksičnost (doze od 50 do 650 mg/kg/dan), uključujući mortalitet pri najvišim dozama.
As with any antihypertensive agent, excessive blood pressure decrease in patients with ischaemic cardiopathy or ischaemic cardiovascular disease could result in a myocardial infarction or stroke. 
Kao i kod bilo kojeg antihipertenziva, prekomjerni pad krvnog tlaka u bolesnika s ishemijskom kardiopatijom ili ishemijskom kardiovaskularnom bolesti može dovesti do infarkta miokarda ili moždanog udara.
Close monitoring of serum potassium in patients at risk is recommended (see section 4.5). 
Preporučuje se česta kontrola serumskog kalija u rizičnih bolesnika (vidjeti dio 4.5.).
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS CALENDAR BLISTER 
PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER ILI STRIP KALENDARSKI BLISTER
Limited accumulation of irbesartan (< 20 %) is observed in plasma upon repeated once-daily dosing. 
Ograničena akumulacija irbesartana (< 20%) zabilježena je u plazmi nakon primjene opetovanih doza jedanput na dan.
Debrecen H-4042 
Pallagi út 13 Debrecen H-4042
Irbesartan Teva belongs to a group of medicines known as angiotensin-II receptor antagonists. 
Irbesartan Teva pripada skupini lijekova koja se naziva antagonisti receptora angiotenzina II.
IDNT was a double blind, controlled, morbidity and mortality trial comparing irbesartan, amlodipine and placebo. 
kontrolirana studija morbiditeta i mortaliteta u kojoj su uspoređivani irbesartan, amlodipin i placebo.
Patients were titrated from 75 mg to a maintenance dose of 300 mg irbesartan, from 2.5 mg to 10 mg amlodipine, or placebo as tolerated. 
Bolesnici su titrirani od 75 mg do doze održavanja od 300 mg irbesartana, od 2,5 mg do 10 mg amlodipina ili placeba do granice podnošljivosti.
Diuretics and other antihypertensive agents 
Diuretici i drugi antihipertenzivni lijekovi
If you accidentally miss a daily dose, just take the next dose as normal. 
Ako ste zaboravili uzeti Irbesartan Teva Ako slučajno zaboravite uzeti dnevnu dozu, uzmite sljedeću dozu kao što to obično i činite.
Contents of the pack and other information What Irbesartan Teva contains 
Sadržaj pakiranja i druge informacije Što Irbesartan
Lithium The combination of lithium and irbesartan is not recommended (see section 4.5). 
Ne preporučuje se kombinacija litija i irbesartana (vidjeti dio 4.5.).
Always take this medicine exactly as your doctor has told you. 
Uvijek uzmite Irbesartan Teva točno onako kako Vam je rekao Vaš liječnik.
Irbesartan at a dose of 150 mg once daily generally provides a better 24 hour blood pressure control than 75 mg. 
Doza od 150 mg irbesartana jedanput na dan općenito osigurava bolju kontrolu krvnog tlaka nego doza od 75 mg u razdoblju od 24 sata.
Do not use this medicine after the expiry date that is stated on the outer carton or foil after EXP. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji ili blisteru iza oznake „EXP“.
• Tablet coating: polydextrose, titanium dioxide, hypromellose and macrogol 4000. 
• Ovojnica tablete: polidekstroza, titanijev dioksid, hipromeloza i makrogol 4000.
It is unknown whether irbesartan or its metabolites are excreted in human milk. 
Nije poznato izlučujuju li se irbesartan ili njegovi metaboliti u majčino mlijeko u ljudi.
When irbesartan is used in patients with impaired renal function, a periodic monitoring of potassium and creatinine serum levels is recommended. 
Kad irbesartan uzimaju bolesnici s oštećenom funkcijom bubrega, preporučuje se periodički kontrolirati serumske razine kalija i kreatinina.
Discontinuation due to any clinical or laboratory adverse event was less frequent for irbesartan-treated patients (3.3 %) than for placebo-treated patients (4.5 %). 
Prekid terapije zbog određenih kliničkih ili laboratorijskih štetnih događaja bio je manje čest u bolesnika liječenih irbesartanom (3,3%) nego u skupini bolesnika koji su primali placebo (4,5%).
if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren 
ako imate šećernu bolest ili oštećenu bubrežnu funkciju i liječite se lijekom za snižavanje krvnog tlaka koji sadrži aliskiren
Other antihypertensive agents may increase the hypotensive effects of irbesartan; however irbesartan has been safely administered with other antihypertensive agents, such as beta-blockers, long-acting calcium channel blockers, and thiazide diuretics. 
Drugi antihipertenzivi mogu pojačati hipotenzivni učinak irbesartana; irbesartan se, međutim, pokazao sigurnim za primjenu s ostalim antihipertenzivnim lijekovima poput beta blokatora, dugodjelujućih blokatora kalcijevih kanala i tiazida.
The following presents the adverse drug reactions that were reported in placebo-controlled trials in which 1,965 hypertensive patients received irbesartan. 
Sljedeća tablica prikazuje nuspojave prijavljene u placebom kontroliranim ispitivanjima, u kojima je 1965 hipertenzivnih bolesnika primalo irbesartan.
The pharmacokinetics of irbesartan were evaluated in 23 hypertensive children after the administration of single and multiple daily doses of irbesartan (2 mg/kg) up to a maximum daily dose of 150 mg for four weeks. 
Farmakokinetika irbesartana proučavana je tijekom 4 tjedna na 23 djece s hipertenzijom, nakon primjene jednokratne i višekratnih dnevnih doza (2 mg/kg), do maksimalne dnevne doze od 150 mg irbesartana.
• The concomitant use of Irbesartan Teva with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 
• Istodobna primjena lijeka Irbesartan Teva s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR < 60 ml/1,73 m2) (vidjeti dijelove 4.5 i 5.1)
The study examined the long-term effects (2 years) of irbesartan on the progression to clinical (overt) proteinuria (urinary albumin excretion rate (UAER) > 300 mg/day, and an increase in UAER of at least 30 % from baseline). 
U studiji su ispitivani dugotrajni učinci (2 godine) irbesartana na progresiju klinički izražene proteinurije (brzina izlučivanja albumina u mokraću (engl. urinary albumin excretion rate, UAER) >300 mg/dan i porast u vrijednostima UAER najmanje 30% od početnih vrijednosti).
Your doctor may need to change your dose and/or to take other precautions: If you are taking an ACE-inhibitor or aliskiren (see also information under the headings “Do not take Irbesartan Teva” and “Warnings and precautions”). 
Liječnik će Vam možda morati promijeniti dozu i/ili poduzeti druge mjere opreza: Ako uzimate neki blokator angiotenzin II receptora (ARB) ili aliskiren (vidjeti također informacije pod naslovima „Nemojte uzimati Irbesartan Teva“ i „Upozorenja i mjere opreza“).
Uncommon: sexual dysfunction 
seksualna disfunkcija
Irbesartan Teva contains sodium 
Irbesartan Teva sadrži natrij
No significant pharmacokinetic or pharmacodynamic interactions were observed when irbesartan was coadministered with warfarin, a medicinal product metabolised by CYP2C9. 
Nisu zabilježene značajne farmakokinetičke i farmakodinamičke interakcije kod istodobne primjene irbesartana i varfarina, lijeka koji se metabolizira pomoću CYP2C9.
Angiotensin-II is a substance produced in the body which binds to receptors in blood vessels causing them to tighten. 
Angiotenzin II tvar je koja se stvara u tijelu i koja se veže na receptore u krvnim žilama te uzrokuje njihovo sužavanje.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. 
U svakoj skupini učestalosti nuspojave su prikazane slijedom prema sve manjoj ozbiljnosti.
Intravascular volume depletion 
Smanjenje intravaskularnog volumena
Irbesartan Teva is indicated in adults for the treatment of essential hypertension. 
Irbesartan Teva je indiciran za liječenje esencijalne hipertenzije u odraslih.
Pack sizes of 50 x 1 and 56 x 1 film-coated tablet in unit dose blisters. 
Pakiranja sa 50 x 1 i 56 x 1 filmom obloženom tabletom u blisterima djeljivim na jedinične doze.
In a randomised trial of 318 hypertensive children and adolescents aged 6 to 16 years, the following adverse reactions occurred in the 3-week double-blind phase: headache (7.9 %), hypotension (2.2 %), dizziness (1.9 %), cough (0.9 %). 
U trotjednoj dvostruko-slijepoj fazi randomizirane kliničke studije u koju je bilo uključeno 318 djece i adolescenata s hipertenzijom u dobi od 6 do 16 godina pojavile su se sljedeće nuspojave povezane s primjenom lijeka: glavobolja (7,9%), hipotenzija (2,2%), omaglica (1,9%), kašalj (0,9%).
Over a subsequent two week period where patients were re-randomized to either active medicinal product or placebo, patients on placebo had increases of 2.4 and 2.0 mm Hg in SeSBP and SeDBP compared to +0.1 and -0.3 mm Hg changes respectively in those on all doses of irbesartan (see section 4.2). 
Tijekom sljedeća dva tjedna kada su bolesnici ponovo randomizirani ili na lijek ili na placebo, bolesnici na placebu imali su porast od 2,4 i 2,0 mmHg za SeSBP i SeDBP, u usporedbi s promjenom od +0,1 i -0,3 mmHg za bolesnike na svim dozama irbesartana (vidjeti dio 4.2.).
Aliskiren-containing products or ACE-inhibitors 
Lijekovi koji sadrže aliskiren ili ACE inhibitori
2031GA Haarlem The Netherlands 
2031GA Haarlem
One side of the tablet debossed with the number “93”. 
Na jednoj strani tablete je utisnut broj “93”.
Rebound hypertension has not been observed. 
Nije zabilježena pojava veće hipertenzije (tzv. rebound hipertenzija).
It is also indicated for the treatment of renal disease in adult patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen (see sections 4.3, 4.4, 4.5 and 5.1). 
Također je indiciran za liječenje bubrežne bolesti u odraslih bolesnika s hipertenzijom i šećernom bolesti tipa 2 u sklopu antihipertenzivne terapije (vidjeti dijelove 4.3, 4.4, 4.5 i 5.1).
In particular, they appeared less favourable in women and non-white subjects (see section 5.1). 
Posebice je bio slabije izražen u žena i bolesnika drugih rasa (vidjeti dio 5.1.).
Hyperkalaemia* occurred more often in diabetic patients treated with irbesartan than with placebo. 
hiperkalijemija* se javljala češće u bolesnika sa šećernom bolesti liječenih irbesartanom nego u skupini koja je primala placebo.
Terms marked with a star (*) refer to the adverse reactions that were additionally reported in > 2 % of diabetic hypertensive patients with chronic renal insufficiency and overt proteinuria and in excess of placebo. 
Pojmovi označeni zvjezdicom (*) odnose se na nuspojave koje su dodatno prijavljene u više od 2% dijabetičkih hipertenzivnih bolesnika s kroničnom insuficijencijom bubrega i manifestnom proteinurijom i to s većom učestalosti nego kod placeba.
Irbesartan does not inhibit ACE (kininase-II), an enzyme which generates angiotensin-II and also degrades bradykinin into inactive metabolites. 
Irbesartan ne inhibira ACE (kininazu II), enzim koji generira angiotenzin-II te degradira bradikinin u neaktivne metabolite.
What Irbesartan Teva is and what it is used for What you need to know before you take Irbesartan Teva How to take Irbesartan Teva Possible side effects 
Što je Irbesartan Teva i za što se koristi Što morate znati prije nego počnete uzimati Irbesartan Teva Kako uzimati Irbesartan Teva
Irbesartan Teva prevents the binding of angiotensin-II to these receptors, causing the blood vessels to relax and the blood pressure to lower. 
Irbesartan Teva sprječava vezanje angiotenzina II na te receptore, uzrokujući opuštanje krvnih žila i sniženje krvnog tlaka.
While similar blood pressure was achieved in all treatment groups, fewer subjects in the irbesartan 300 mg group (5.2 %) than in the placebo (14.9 %) or in the irbesartan 150 mg group (9.7 %) reached the endpoint of overt proteinuria, demonstrating a 70 % relative risk reduction versus placebo (p = 0.0004) for the higher dose. 
Dok je sličan krvni tlak postignut u svim ispitivanim skupinama, manje bolesnika u skupini koja je primala 300 mg irbesartana (5,2%) dostiglo je ishod manifestne proteinurije u odnosu na skupinu koja je primala placebo (14,9%) ili na skupinu koja je primala 150 mg irbesartana (9,7%), pokazujući smanjenje relativnog rizika za 70% pri primjeni veće doze u odnosu na placebo (p=0,0004).
dizziness, orthostatic dizziness* 
Često: omaglica, ortostatska omaglica*